Atopic Dermatitis – Experience with Dupilumab Therapy during Pandemic
Authors:
P. Brodská; J. Říčař; P. Cetkovská
Authors‘ workplace:
Dermatovenerologická klinika, Fakultní nemocnice Plzeň, přednosta prof. MUDr. Karel Pizinger, CSc.
Published in:
Čes-slov Derm, 96, 2021, No. 4, p. 186-190
Category:
Case Reports
Overview
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the medical community has faced major challenges that affect disease management in all areas. Dermatologists have to choose appropriate treatment strategy taking into consideration risk of infection COVID-19 in patients on systemic therapy of moderate to severe atopic dermatitis. Out of a total of 15 of our patients with severe atopic eczema treated with dupilumab, 8 had already been infected with SARS-CoV-2. Our experience showed that discontinuation of one dose of dupilumab did not lead to loss of efficacy. Our patients were treated with the same effect of dupilumab therapy weeks and months after COVID-19 infection. Most of our patients has experienced worsening of atopic dermatitis and mild course of COVID-19 infection, independently dupilumab was discontinued or not. Patients with mild course of COVID-19 infection continued with dupilumab therapy and did not observe any worsening of COVID-19 symptoms. Our observations have confirmed the data from literature showing that dupilumab can be safely used during the COVID-19 pandemic.
Sources
1. BRODSKA, P., PANZNER, P., SEDLACEK, D., TERL, M., CETKOVSKA, P. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection. Dermatol Ther, 2020, 33(6), p. 14159.
2. COLOMBO, D., CHIMENTI, S., GROSSI, P. et al. Prevalence of past and reactivated viral infections and efficacy of cyclosporine as monotherapy or in combination in patients with psoriatic arthritis – synergy study: a longitudinal observation study. Biomed Res Int, 2014, 941767.
3. D´ERME, A. M., ROMANELLI, M., CHIRICOZZI, A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des, Devel Ther, 2017, 11, p. 1473–1480.
4. EICHENFIELD, L. F., BIEBER, T., BECK, L. A. et al. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol, 2019, 20, p. 443–456.
5. FENG, Y., LING, Y., BAI, T. et al. COVID-19 with different severities: A multicenter Study of Clinical Features. Am J Respir Crit Care Med, 2020, 201, p. 1380–1388.
6. CHEN, G., WU, D., GUO, W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 2020, 130, p. 2620–2629.
7. MARKO, M., PAWLICZAK, R. Can we safely use systemic treatment in atopic dermatitis during the covid- 19 pandemic? Overview of selected conventional and biologic systemic therapies. Expert Rev Clin Immunol, 2021, 24, p. 1–9.
8. ORDONEZ-RUBIANO, M. F., RUBIANO-MOJICA, P. C., CASAS, M. Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis. Int J Dermatol, 2021, 60, p. 514.
9. PATRUNO, C., STINGENI, L., FABBROCINI, G. et al. Dupilumab and COVID-19: What should we expect? Dermatol Ther, 2020, 33, p. 13502.
10. RICARDO, J. W., LIPNER, S. R. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther, 2020, 33, p. 13687.
11. ROSSI, M., ROVATI, C., ARISI, M. et al. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic. A single-center real-life experience. Dermatol Ther, 2020, 33, p. 13765.
12. SHELLEY, K., UPPAL, B. S., DONOVAN, G. et al. Management of Atopic Dermatitis During the COVID-19 Pandemic. Practical Dermatology, 2020, p. 48–64.
13. SIMPSON, E. L., BIEBER, T., GUTTMAN-YASSKY E. et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med, 2016, 375, p. 2335–2348.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2021 Issue 4
Most read in this issue
- Skin Development and its Barrier Function
- Pustules and Crusts on the Scalp – Folliculitis decalvans. Minireview.
- Atopic Dermatitis – Experience with Dupilumab Therapy during Pandemic
- The Influence of Long Term Therapy with Adalimumab on Biomarkers of Systemic Inflammation in Psoriasis